Temporal changes in free iron levels after brain ischemia. Relevance to the timing of iron chelation therapy in stroke

Neurochemistry International

Volumn 52, Issue 8, 2008, Pages 1442-1448

  Millerot Serrurot, Emilie ^a,c   Bertrand, Nathalie ^a,c   Mossiat, Claude ^a,c   Faure, Philippe ^c   Prigent Tessier, Anne ^a,c   Garnier, Philippe ^a,c   Bejot, Yannick ^b   Giroud, Maurice ^b   Beley, Alain ^c   Marie, Christine ^a,c  

^a INSERM   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Brain ischemia; Ferritin; Free iron; Iron chelator; Rat

Indexed keywords

2,2' BIPYRIDINE; FERRITIN; IRON; IRON CHELATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN LEVEL; BRAIN TISSUE; CHELATION THERAPY; CONTROLLED STUDY; DRUG EFFECT; FERRITIN BLOOD LEVEL; IRON BLOOD LEVEL; MALE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RAT; STROKE; TREATMENT OUTCOME;

2,2'-DIPYRIDYL; ANIMALS; BRAIN ISCHEMIA; CHELATING AGENTS; CHELATION THERAPY; DISEASE MODELS, ANIMAL; FERRITINS; INTRACRANIAL THROMBOSIS; IRON; IRON CHELATING AGENTS; MALE; PHOTIC STIMULATION; RATS; RATS, WISTAR; STROKE; TIME FACTORS; UP-REGULATION;

RATTUS;

EID: 44749091010     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2008.04.002     Document Type: Article

References (48)

1. Boquillon M., Boquillon J.P., and Bralet J. Photochemically induced, graded cerebral infarction in the mouse by laser irradiation evolution of brain edema. J. Pharmacol. Toxicol. Methods 27 (1992) 1-6
2. Bralet J., Schreiber L., and Bouvier C. Effect of acidosis and anoxia on iron delocalization from brain homogenates. Biochem. Pharmacol. 43 (1993) 979-983
3. Burggraf D., Martens H.K., Dichgans M., and Hamann G.F. Rt-PA causes a dose-dependent increase in the extravasation of cellular and non-cellular blood elements after focal cerebral ischemia. Brain Res. 1164 (2007) 55-62
4. Chi S.I., Wang C.K., Chen J.J., Chau L.Y., and Lin T.N. Differential regulation of H- and L-ferritin messenger RNA subunits, ferritin protein and iron following focal cerebral ischemia-reperfusion. Neuroscience 100 (2000) 475-484
5. Delaby C., Pilard N., Hetet G., Drise F., Granchamps B., Beumont C., and Canonne-Hergaux F. A physiological model to study iron recycling in macrophages. Exp. Cell Res. 310 (2005) 13-53
6. Demougeot C., Marie C., and Beley A. Importance of iron location in iron-induced hydroxyl radical production by brain slices. Life Sci. 67 (2000) 399-410
7. Demougeot C., Bertrand N., Prigent-Tessier A., Garnier P., Mossiat C., Giroud M., Marie C., and Beley A. Reversible loss of N-acetyl-aspartate in rats subjected to long-term focal cerebral ischemia. J. Cereb. Blood Flow Metab. 23 (2003) 482-489
8. Demougeot C., Methy D., Prigent-Tessier A., Garnier P., Bertrand N., Guilland J.C., Beley A., and Marie C. Effects of a direct injection of liposoluble iron into rat striatum. Importance of the rate of iron delivery to cells. Free Radic. Res. 37 (2003) 59-67
9. Demougeot C., Van Hoecke M., Bertrand N., Prigent-Tessier A., Mossiat C., Beley A., and Marie C. Cytoprotective efficacy and mechanisms of the liposoluble iron chelator 2,2′-dipyridyl in the rat photothrombotic ischemic stroke model. J. Pharmacol. Exp. Ther. 311 (2004) 1080-1087
10. Dietrich W.D., Busto R., Watson B.D., Scheinberg P., and Ginsberg M.D. Photochemically induced cerebral infarction. II. Edema and blood-brain barrier disruption. Acta Neuropathol. (Berl.) 72 (1987) 326-334
11. Eisenstein R.S. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Ann. Rev. Nutr. 20 (2000) 627-662
12. Fagan S.C., Hess D.C., Hohnadel E.J., Ploocl D.M., and Ergul A. Targets for vascular protection after acute ischemic stroke. Stroke 35 (2004) 2220-2225
13. Fahmy M., and Young S. Modulation of iron metabolism in monocyte cell line U937 by inflammatory cytokines: changes in transferrin uptake, iron handling and ferritin mRNA. Biochem. J. 296 (1993) 175-181
14. Fleisher J.E., Lanier W.L., Milde J.H., and Michenfelder J.D. Failure of deferoxamine, an iron chelator, to improve neurological outcome following complete cerebral ischemia in dogs. Stroke 18 (1987) 124-1124
15. Freret T., Valable S., Chazalviel L., Saulnier R., Mackenzie E.T., Petit E., Bernaudin M., Boulouard M., and Schumann-Bard P. Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat. Eur. J. Neurosci. 23 (2006) 1757-1765
16. Grome J.J., Gojowczyk G., Hofmann W., and Graham D.I. Quantitation of photochemocally induced focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metabol. 8 (1988) 89-95
17. Haddad M., Rhinn H., Bloquel C., Coqueran B., Szabo C., Plotkine M., Scherman D., and Margaill I. Anti-inflammatory effects of PJ34, a poly(ADP(ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice. Br. J. Pharmacol. 149 (2006) 23-30
18. Hidalgo C., Carasco M.A., Munoz P., and Nunez M.T. A role for reactive oxygen/nitrogen species and iron on neuronal synaptic plasticity. Antioxid. Redox Signal 9 (2007) 245-255
19. Hurn P.D., Koehler R.C., Blizzard K.K., and Traystman R.J. Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. Stroke 26 (1995) 688-694
20. Ishimaru H., Ishikawa K., Ohe Y., Takahashi A., Tatemoto K., and Maruyama Y. Activation of iron handling system within the gerbil hippocampus after cerebral ischemia. Brain Res. 726 (1996) 23-30
21. Iwanami J., Mogi M., Okamoto S., Gao X.Y., Li J.M., Min L.J., Ide A., Tsukuda K., Iwai M., and Horiuchi M. Pretreatment with eplerone reduce stroke volume in mouse middle cerebral artery occlusion model. Eur. J. Pharmacol. 566 (2007) 153-169
22. Ji B., Maeda J., Higuchi M., Inoue K., Akita H., Harashima H., and Suhara T. Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci. 78 (2006) 851-855
23. Kim G.W., Lewen A., Copin J., Watson B.D., and Chan P.H. The cytosolic antioxidant, copper/zinc superoxide dismutase, attenuates blood-brain barrier disruption and oxidative cellular injury after photothrombotic cortical ischemia in mice. Neuroscience 105 (2001) 1007-1018
24. Komara J.S., Nayini N.R., Bialick H.A., Indrieri R.J., Evans A.T., Garritano A.M., Hoehner T.J., Jacobs W.A., Huang R.R., Krause G.S., et al. Brain iron delocalization and lipid peroxidation following cardiac arrest. Ann. Emerg. Med. 15 (1986) 384-389
25. Kompala S.D., Babbs C.F., and Blaho K.E. Effect of deferoxamine on late deaths following CPR in rats. Ann. Emerg. Med. 15 (1986) 405-407
26. Kondo Y., Ogawa N., Asanuma M., Ota Z., and Mori A. Regional differences in late-onset iron deposition, ferritin, transferrin, astrocyte proliferation, and microglial activation after transient forebrain ischemia in rat brain. J. Cereb. Blood Flow Metab. 15 (1995) 216-226
27. Lambertsen K.L., Meldgaard M., Ladeby R., and Finsen B. A quantitative study of microglial-macrophage synthesis of tumor necrosis factor during acute and late focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 25 (2005) 119-135
28. Lipscomb D.C., Gorman L.G., Traystman R.J., and Hurn P.D. Low molecular weight iron in cerebral ischemic acidosis in vivo. Stroke 29 (1998) 487-492
29. Liu G., Men P., Harris P.L., Rolston R.K., Perry G., and Smith M.A. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurological disorders associated with trace metal imbalance. Neurosci. Lett. 406 (2006) 189-193
30. Lloyd J.B., Cable H., and Rice-Evans C. Evidence that desferrioxamine cannot enter cells by passive diffusion. Biochem. Pharmacol. 41 (1991) 361-1363
31. Mac Millan V., Fridovich I., and Davis J. Failure of iron chelators to protect against cerebral infarction in hypoxia-ischemia. Can. J. Neurol. Sci. 20 (1993) 41-43
32. Margaill I., Plotkine M., and Lerouet D. Antioxidant strategies in the treatment of stroke. Free Radic. Biol. Med. 39 (2005) 429-443
33. Méthy D., Bertrand N., Prigent-Tessier A., Mossiat C., Stanimirovic D., Beley A., and Marie C. Beneficial effect of dipyridyl, a liposoluble iron chelator against focal cerebral ischemia: in vivo and in vitro evidence of protection of cerebral endothelial cells. Brain Res. 1193 (2007) 136-142
34. Moos T., Oates P.S., and Morgan E.H. Iron-independent neuronal expression of transferrin receptor mRNA in the rat. Mol. Brain Res. 72 (1999) 231-234
35. Nagayama T., Lan J., Henshall D.C., Chen D., O'Horo C., Simon R.P., and Chen J. Induction of oxidative damage in the peri-infarct region after permanent focal cerebral ischemia. J. Neurochem. 75 (2000) 1716-1728
36. Oubidar M., Boquillon M., Marie C., Schreiber L., and Bralet J. Ischemia-induced brain iron delocalization: effect of iron chelators. Free Radic. Biol. Med. 16 (1994) 861-867
37. Oubidar M., Marie C., Mossiat C., and Bralet J. Effects of increasing intracellular reactive iron level on cardiac function and oxidative injury in the isolated rat heart. J. Mol. Cell Cardiol. 28 (1996) 1769-1776
38. Patt A., Horesh I.R., Berger E.M., Harken A.H., and Repine J.E. Iron depletion or chelation reduces ischemia/reperfusion-induced edema in gerbil brains. J. Pediatr. Surg. 25 (1990) 224-228
39. Paul T. Effect of a prolonged superoxide flux on transferrin and ferritin. Arch. Biochem. Biophys. 382 (2000) 253-261
40. Peeters-Scholte C., Braun K., Koster J., Kops N., Blomgren K., Buonocore G., van Buul-Offers S., Hadberg H., Nicolay K., van Bel F., and Groenendaal F. Effects of allopurinol and deferoxamine on reperfusion injury of the brain in newborn piglets after neonatal hypoxia-ischemia. Pediatr. Res. 54 (2003) 516-522
41. Ponka P. Cellular iron metabolism. Kidney Int. Suppl. 69 (1999) S2-S11
42. Prass K., Ruscher K., Karsch M., Isaev N., Megow D., Priller J., Scharff A., Dirnagl U., and Meisel A. Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J. Cereb. Blood Flow Metab. 22 (2002) 520-525
43. Rothenberger S., Food M.R., Gabathuler R., Kennard M.L., Yamada T., Yasuhara O., McGeer P.L., and Jefferies W.A. Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium. Brain Res. 712 (1996) 117-121
44. Shadid M., Buonocore G., Groenendaal F., Moison R., Ferrali M., Berger H.M., and van Bel F. Effect of deferoxamine and allopurinol on non-protein-bound iron concentration in plasma and cortical brain tissue of newborn lambs following hypoxia-ischemia. Neurosci. Lett. 248 (1998) 5-8
45. Soloniuk D.S., Perkins E., and Wilson J.R. Use of allopurinol and deferoxamine in cellular protection during ischemia. Surg. Neurol. 38 (1992) 110-113
46. Van Hoecke M., Prigent-Tessier A., Bertrand N., Prevotat L., Marie C., and Beley A. Apoptotic cell death progression after photothrombotic focal cerebral ischaemia: effects of the lipophilic iron chelator 2,2′-dipyridyl. Eur. J. Neurosci. 22 (2005) 1045-1056
47. Van Hoecke M., Prigent-Tessier A., Garnier P., Bertrand N., Filomenko R., Bettaieb A., Marie C., and Beley A. Evidence of HIF-1 functional binding activity to caspase-3 promotor after photothrombotic cerebral ischemia. Mol. Cell Neurosci. 34 (2007) 40-47
48. Weiss G. Modification of iron regulation by the inflammatory response. Best Pract. Res. Clin. Haematol. 18 (2005) 183-201